Christopher James Sampson

Personal Details

First Name:	Christopher
Middle Name:	James
Last Name:	Sampson
Suffix:
RePEc Short-ID:	psa1048
	[This author has chosen not to make the email address public]
	http://www.chrissampson.me
	2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB UK
	+44 (0)20 7747 8866
Twitter:	@chrissampson87
Mastodon:	@ChrisSampson87@veganism.social
Bluesky:	@chrissampson87.bsky.social
Terminal Degree:	2020 (from RePEc Genealogy)

Affiliation

Office of Health Economics

London, United Kingdom
http://www.ohe.org/
RePEc:edi:ohecouk (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. Hernández-Alava, Mónica & Sampson, Christopher & Wailoo, Allan, 2013. "Happy and healthy: a joint model of health and life satisfaction," MPRA Paper 49766, University Library of Munich, Germany.

   Mentioned in:

   1. #HEJC papers for October 2013
      by academichealtheconomists in The Academic Health Economists' Blog on 2013-10-01 04:30:26
   2. Chris Sampson’s journal round-up for 13th March 2017
      by Chris Sampson in The Academic Health Economists' Blog on 2017-03-13 17:00:42
2. Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward , 2019. "Transparency in Decision Modelling: What, Why, Who and How?," PharmacoEconomics, Springer, vol. 37(11), pages 1355-1369, November.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 9th March 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-03-09 12:00:00
3. Sampson, Christopher & James, Marilyn & Whynes, David, 2013. "The relationship between individual risk and cost-effectiveness in screening interventions," MPRA Paper 51799, University Library of Munich, Germany.

   Mentioned in:

   1. New working paper – ‘The relationship between individual risk and cost-effectiveness in screening interventions’
      by Chris Sampson in Chris Sampson on 2013-12-03 12:00:55
   2. Thesis Thursday: Chris Sampson
      by captaincanaway in The Academic Health Economists' Blog on 2020-08-20 06:00:04
4. Christopher James Sampson & Tim Wrightson, 2017. "Model Registration: A Call to Action," PharmacoEconomics - Open, Springer, vol. 1(2), pages 73-77, June.

   Mentioned in:

   1. Meeting round-up: Health Economists’ Study Group (HESG) Winter 2018
      by Chris Sampson in The Academic Health Economists' Blog on 2018-01-19 07:00:03
   2. Chris Sampson’s journal round-up for 1st April 2019
      by Chris Sampson in The Academic Health Economists' Blog on 2019-04-01 11:00:21
5. Chris Sampson;Martina Garau, 2019. "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefing 002146, Office of Health Economics.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 7th September 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-09-07 11:00:07
6. Author Profile
   1. 10 steps to open access success
      by Chris Sampson in Chris Sampson on 2015-10-21 10:00:10

Working papers

1. Chris Sampson;Martina Garau, 2019. "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefing 002146, Office of Health Economics.

   Cited by:

   1. Amanda Whittal & Michela Meregaglia & Elena Nicod, 2021. "The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 14(5), pages 485-503, September.
   2. C. Simone Sutherland & Pollyanna Hudson & Stephen Mitchell & Noman Paracha, 2022. "Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers," PharmacoEconomics, Springer, vol. 40(1), pages 39-67, April.
   3. Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland, 2022. "Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management," PharmacoEconomics, Springer, vol. 40(1), pages 11-38, April.

2. Mikel Berdud;Martina Garau;Margherita Neri;Phill O’Neill;Chris Sampson;Adrian Towse, 2018. "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Grant-Funded Research 002040, Office of Health Economics.

   Cited by:

   1. Dubois, Pierre & Magnac, Thierry, 2024. "Optimal intertemporal curative drug expenses: The case of hepatitis C in France," Journal of Health Economics, Elsevier, vol. 94(C).
      • Pierre Dubois & Thierry Magnac, 2024. "Optimal Intertemporal Curative Drug Expenses: The Case of Hepatitis C in France," Post-Print hal-04501256, HAL.
      • Magnac, Thierry & Dubois, Pierre, 2023. "Optimal Intertemporal Curative Drug Expenses: The Case of Hepatitis C in France," TSE Working Papers 23-1402, Toulouse School of Economics (TSE).

Articles

1. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.

   Cited by:

   1. Sampson, Chris & Cookson, Graham, 2024. "Marginal cost per QALY estimates: What are they good for?," Health Policy, Elsevier, vol. 142(C).

2. Chris Sampson & Isobel Firth & Adrian Towse, 2021. "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al," Medical Decision Making, , vol. 41(3), pages 255-257, April.

   Cited by:

   1. Marta O. Soares & Mark J. Sculpher & Karl Claxton, 2021. "Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.†by Sampson, Firth, and Towse," Medical Decision Making, , vol. 41(3), pages 258-260, April.

3. Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward , 2019. "Transparency in Decision Modelling: What, Why, Who and How?," PharmacoEconomics, Springer, vol. 37(11), pages 1355-1369, November.

   Cited by:

   1. Kai Jia & Nan Zhang, 2022. "Categorization and eccentricity of AI risks: a comparative study of the global AI guidelines," Electronic Markets, Springer;IIM University of St. Gallen, vol. 32(1), pages 59-71, March.
   2. Harvard, Stephanie & Werker, Gregory R. & Silva, Diego S., 2020. "Social, ethical, and other value judgments in health economics modelling," Social Science & Medicine, Elsevier, vol. 253(C).
   3. Josh J. Carlson & Surrey M. Walton & Anirban Basu & Richard H. Chapman & Jonathan D. Campbell & R. Brett McQueen & Steven D. Pearson & Daniel R. Touchette & David Veenstra & Melanie D. Whittington & D, 2019. "Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States," PharmacoEconomics, Springer, vol. 37(11), pages 1321-1327, November.
   4. Harvard, Stephanie & Winsberg, Eric B., 2024. "‘Managing values’ in health economics modelling: Philosophical and practical considerations," Social Science & Medicine, Elsevier, vol. 358(C).

4. Christopher James Sampson & Tim Wrightson, 2017. "Model Registration: A Call to Action," PharmacoEconomics - Open, Springer, vol. 1(2), pages 73-77, June.

   Cited by:

   1. Emma McManus & David Turner & Tracey Sach, 2019. "Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics," PharmacoEconomics, Springer, vol. 37(11), pages 1371-1381, November.
   2. Hannah Christensen & Hareth Al-Janabi & Pierre Levy & Maarten J. Postma & David E. Bloom & Paolo Landa & Oliver Damm & David M. Salisbury & Javier Diez-Domingo & Adrian K. Towse & Paula K. Lorgelly & , 2020. "Economic evaluation of meningococcal vaccines: considerations for the future," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(2), pages 297-309, March.
      • Hannah Christensen & Hareth Al-Janabi & Pierre Lévy & Maarten J. Postma & David E. Bloom & Paolo Landa & David M. Salisbury & Javier Diez-Domingo & Adrian K. Towse & Paula K. Lorgelly & Koonal K. Shah, 2020. "Economic evaluation of meningococcal vaccines: considerations for the future," Post-Print hal-03120553, HAL.
   3. Philip Clarke & John Buckell & Adrian Barnett, 2020. "Registered Reports: Time to Radically Rethink Peer Review in Health Economics," PharmacoEconomics - Open, Springer, vol. 4(1), pages 1-4, March.
   4. Renée J. G. Arnold & Sean Ekins, 2017. "Ahead of Our Time: Collaboration in Modeling Then and Now," PharmacoEconomics, Springer, vol. 35(9), pages 975-976, September.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

List Editorship

This author manages the following RePEc Biblio topics, reading lists or publication compilations:

1. Sheffield Health Economics Alumni

Featured entries

This author is featured on the following reading lists, publication compilations, Wikipedia, or ReplicationWiki entries:

1. Sheffield Health Economics Alumni

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 9 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.

1. NEP-HEA: Health Economics (8) 2013-08-31 2013-09-28 2013-12-06 2018-05-21 2018-10-08 2019-03-25 2020-12-07 2021-07-19. Author is listed
2. NEP-INO: Innovation (2) 2018-10-08 2018-10-15
3. NEP-COM: Industrial Competition (1) 2018-10-15
4. NEP-HAP: Economics of Happiness (1) 2013-09-28
5. NEP-HIS: Business, Economic and Financial History (1) 2018-10-08
6. NEP-TID: Technology and Industrial Dynamics (1) 2018-10-15
7. NEP-UPT: Utility Models and Prospect Theory (1) 2020-12-07

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Christopher James Sampson should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.